Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

terbinafine hydrochloride

×

Overview

What is Lamisil?

LAMISIL Tablets contain the synthetic allylamine antifungal compound terbinafine hydrochloride.

Chemically, terbinafine hydrochloride is (E)--(6,6-dimethyl-2-hepten-4-ynyl)--methyl-1-naphthalenemethanamine hydrochloride. The empirical formula CHCIN with a molecular weight of 327.90, and the following structural formula:

Terbinafine hydrochloride is a white to off-white fine crystalline powder. It is freely soluble in methanol and methylene chloride, soluble in ethanol, and slightly soluble in water.

Each tablet contains:

Active Ingredients:

Inactive Ingredients:



What does Lamisil look like?



What are the available doses of Lamisil?

Tablet, 250 mg ()

What should I talk to my health care provider before I take Lamisil?

How should I use Lamisil?

LAMISIL (terbinafine hydrochloride) Tablets are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). 

Prior to initiating treatment, appropriate nail specimens for laboratory testing [potassium hydroxide (KOH) preparation, fungal culture, or nail biopsy] should be obtained to confirm the diagnosis of onychomycosis.

Before administering LAMISIL Tablets, evaluate patients for evidence of chronic or active liver disease .


What interacts with Lamisil?

Sorry No Records found


What are the warnings of Lamisil?

Sorry No Records found


What are the precautions of Lamisil?

Sorry No Records found


What are the side effects of Lamisil?

Sorry No records found


What should I look out for while using Lamisil?

LAMISIL Tablets are contraindicated in patients with:

• History of allergic reaction to oral terbinafine because of the risk of anaphylaxis  

• Chronic or active liver disease 


What might happen if I take too much Lamisil?

Clinical experience regarding overdose with oral terbinafine is limited. Doses up to 5 grams (20 times the therapeutic daily dose) have been taken without inducing serious adverse reactions. The symptoms of overdose included nausea, vomiting, abdominal pain, dizziness, rash, frequent urination, and headache.


How should I store and handle Lamisil?

Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature]. Dispense in a tight container as defined in the USP/NF.LAMISILTablets are supplied as white to yellow-tinged white circular, biconvex, beveled tablets containing 250 mg of terbinafine imprinted with “LAMISIL” in circular form on one side and code “250” on the other.Bottles of 100 tablets                                                             NDC 0078-0179-05Bottles of 30 tablets                                                             NDC 0078-0179-15Store LAMISIL Tablets below 25°C (77°F); in a tight container. Protect from light.LAMISILTablets are supplied as white to yellow-tinged white circular, biconvex, beveled tablets containing 250 mg of terbinafine imprinted with “LAMISIL” in circular form on one side and code “250” on the other.Bottles of 100 tablets                                                             NDC 0078-0179-05Bottles of 30 tablets                                                             NDC 0078-0179-15Store LAMISIL Tablets below 25°C (77°F); in a tight container. Protect from light.LAMISILTablets are supplied as white to yellow-tinged white circular, biconvex, beveled tablets containing 250 mg of terbinafine imprinted with “LAMISIL” in circular form on one side and code “250” on the other.Bottles of 100 tablets                                                             NDC 0078-0179-05Bottles of 30 tablets                                                             NDC 0078-0179-15Store LAMISIL Tablets below 25°C (77°F); in a tight container. Protect from light.LAMISILTablets are supplied as white to yellow-tinged white circular, biconvex, beveled tablets containing 250 mg of terbinafine imprinted with “LAMISIL” in circular form on one side and code “250” on the other.Bottles of 100 tablets                                                             NDC 0078-0179-05Bottles of 30 tablets                                                             NDC 0078-0179-15Store LAMISIL Tablets below 25°C (77°F); in a tight container. Protect from light.


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Terbinafine is an allylamine antifungal .

Non-Clinical Toxicology
LAMISIL Tablets are contraindicated in patients with:

• History of allergic reaction to oral terbinafine because of the risk of anaphylaxis  

• Chronic or active liver disease 

The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving glyburide, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving glyburide, the patient should be observed closely for loss of control. An increased risk of liver enzyme elevations was observed in patients receiving glyburide concomitantly with bosentan. Therefore concomitant administration of glyburide and bosentan is contraindicated. Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving glyburide, the patient should be closely observed for loss of control. When such drugs are withdrawn from a patient receiving glyburide, the patient should be observed closely for hypoglycemia. A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide. The mechanism for this interaction is not known. A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical or vaginal preparations of miconazole is not known. Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cwere observed, but were highly variable. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. Colesevelam Concomitant administration of colesevelam and glyburide resulted in reductions in glyburide AUC and C of 32% and 47%, respectively. The reductions in glyburide AUC and C were 20% and 15%, respectively when administered 1 hour before, and not significantly changed (-7% and 4%, respectively) when administered 4 hours before colesevelam. Topiramate: A drug-drug interaction study conducted in patients with type 2 diabetes evaluated the steady-state pharmacokinetics of glyburide (5 mg/day) alone and concomitantly with topiramate (150 mg/day). There was a 22% decrease in Cmax and a 25% reduction in AUC for glyburide during topiramate administration. Systemic exposure (AUC) of the active metabolites, 4-trans-hydroxy-glyburide (M1) and 3-cis-hydroxyglyburide (M2), was also reduced by 13% and 15%, and C was reduced by 18% and 25%, respectively. The steady-state pharmacokinetics of topiramate were unaffected by concomitant administration of glyburide.

LAMISIL Tablets are contraindicated for patients with chronic or active liver disease. Before prescribing LAMISIL Tablets, perform liver function tests because hepatotoxicity may occur in patients with and without preexisting liver disease. Cases of liver failure, some leading to liver transplant or death, have occurred with the use of LAMISIL Tablets in individuals with and without preexisting liver disease.

In the majority of liver cases reported in association with use of LAMISIL Tablets, the patients had serious underlying systemic conditions. The severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease. Periodic monitoring of liver function tests is recommended. Discontinue LAMISIL Tablets if biochemical or clinical evidence of liver injury develops.

Warn patients prescribed LAMISIL Tablets and/or their caregivers to report immediately to their healthcare providers any symptoms or signs of persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain or jaundice, dark urine, or pale stools. Advise patients with these symptoms to discontinue taking oral terbinafine, and immediately evaluate the patient’s liver function. 

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).